Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Retained Earnings (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Retained Earnings for 6 consecutive years, with $242000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.02% to $242000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $242000.0 through Dec 2025, up 100.02% year-over-year, with the annual reading at $242000.0 for FY2025, 100.02% up from the prior year.
  • Retained Earnings hit $242000.0 in Q4 2025 for Lyell Immunopharma, up from -$1.5 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $242000.0 in Q4 2025 to a low of -$1.5 billion in Q3 2025.
  • Historically, Retained Earnings has averaged -$679.6 million across 5 years, with a median of -$688.8 million in 2022.
  • Biggest YoY gain for Retained Earnings was 100.02% in 2025; the steepest drop was 362616.62% in 2025.
  • Year by year, Retained Earnings stood at -$584.4 million in 2021, then soared by 98.7% to -$7.6 million in 2022, then plummeted by 13087.42% to -$1.0 billion in 2023, then plummeted by 34.23% to -$1.3 billion in 2024, then skyrocketed by 100.02% to $242000.0 in 2025.
  • Business Quant data shows Retained Earnings for LYEL at $242000.0 in Q4 2025, -$1.5 billion in Q3 2025, and -$1.4 billion in Q2 2025.